2022 Precision Oncology Patient Innovation Awards (POPIA)
Now Open for Worldwide Submissions
Bayer is proud to support the second global POPIA, which are aimed at fostering innovation and collaboration to improve access to precision oncology care and tackle inequalities for people with cancer around the world. The awards are particularly focused on helping people with cancer types that are known to harbor rare genomic alterations and which may benefit from tumor testing.
Apply for the Precision Oncology Patient Innovation Awards
Step 1: Download the application
Step 2: Submit a proposal
Next Important Date
June 10, 2022 – Deadline for initial applications
Why Precision Oncology?
Precision oncology is a growing field where cancers are tested and treated according to their unique DNA fingerprint.
Understanding what might be driving a person’s cancer growth, and their likely response to specific treatments, is intended to refine diagnosis and guide ongoing care.
About the Award
The awards are open to nonprofit organizations, including patient advocacy groups, educational institutions, and officially recognized healthcare/research facilities. Three grants will be awarded in 2022 for $30,000 each. The 2022 awards will be appointed to innovative programs tackling access to biomarker testing in the following cancer types:
- Lung Cancer
- Thyroid Cancer
- Rarer Cancer Types such as pediatric cancers, sarcomas, and other solid tumors that are known to harbor rare, actionable genomic alterations. Types of genomic alterations can include KRAS, HER2, BRAF, EGFR, ALK, ROS1, NTRK gene fusions, and many more
Successful applicants will be chosen by an independent, non-Bayer review panel from the cancer community.
Who Can Apply
Applications will be accepted from nonprofit organizations, including patient advocacy groups, educational institutions, and officially recognized healthcare/research facilities from around the world, unless prohibited by national law.
Applications from individuals will not be allowed.
Collaborations between institutions, including between patient groups and research facilities, are welcome.
Please designate a lead organization in the application.
